Validating a Proteomic Signature of Severe COVID-19

Validating a Proteomic Signature of Severe COVID-19

OBJECTIVES:. COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19. DESIGN:. Prospective obs...

Full description

Bibliographic Details
Main Authors: Christopher V. Cosgriff, MD, MPH, Todd A. Miano, PhD, PharmD, Divij Mathew, PhD, Alexander C. Huang, MD, PhD, Heather M. Giannini, MD, MS, Leticia Kuri-Cervantes, PhD, M. Betina Pampena, PhD, Caroline A. G. Ittner, PhD, Ariel R. Weisman, MS, Roseline S. Agyekum, BS, Thomas G. Dunn, BS, Oluwatosin Oniyide, BS, Alexandra P. Turner, BS, Kurt D’Andrea, BS, Sharon Adamski, BS, Allison R. Greenplate, PhD, Brian J. Anderson, MD, MSCE, Michael O. Harhay, PhD, Tiffanie K. Jones, MD, MPH, MSCE, John P. Reilly, MD, MSCE, Nilam S. Mangalmurti, MD, Michael G. S. Shashaty, MD, MSCE, Michael R. Betts, PhD, E. John Wherry, PhD, Nuala J. Meyer, MD, MS
Format: Article
Language:English
Published: Wolters Kluwer 2022-12-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000000800

Internet

http://journals.lww.com/10.1097/CCE.0000000000000800

Similar Items